Publisher
Springer International Publishing
Reference5 articles.
1. Mengel H, Jansen JA, Sommerville K, Jonkman JHG, Wesnes K, Cohen A, Carlson GF, Marshal LR, Snel S, Dirach J, Kastberg H. Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam, or ethanol. Epilepsia. 1995;36 (Suppl 3):S160.
2. Snel S, Jansen JA, Pedersen PC, Jonkman JH, van Heiningen PN. Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin. Eur J Clin Pharmacol. 1998;54:355–7.
3. Thomsen MS, Groes L, Agerso H, Kruse T. Lack of pharmacokinetic interaction between tiagabine and erythromycin. J Clin Pharmacol. 1998;38:1051–6.
4. Burstein AH, Boudreau EA, Theodore WH. Increase in tiagabine serum concentration with coadministration of gemfibrozil. Ann Pharmacother. 2009;43:379–82.
5. Richens A, Marshall RW, Dirach J, Jansen JA, Snel P, Pedersen PC. Absence of interaction between tiagabine, a new antiepileptic drug, and the benzodiazepine triazolam. Drug Metabol Drug Interact. 1998;14:159–77.